{"altmetric_id":210390,"counts":{"readers":{"mendeley":330,"citeulike":0,"connotea":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":2},"total":{"posts_count":4},"f1000":{"unique_users_count":2,"unique_users":["Nature reviews. Clinical oncology","F1000Prime"],"posts_count":2}},"citation":{"abstract":"Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as monotherapy for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) was designed to evaluate the efficacy and safety of panitumumab plus infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as initial treatment for mCRC.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Douillard JY","Siena S","Cassidy J","Tabernero J","Burkes R","Barugel M","Humblet Y","Bodoky G","Cunningham D","Jassem J","Rivera F","Koc\u00e1kova I","Ruff P","B\u0142asi\u0144ska-Morawiec M","\u0160makal M","Canon JL","Rother M","Oliner KS","Wolf M","Gansert J","Jean-Yves Douillard","Salvatore Siena","James Cassidy","Josep Tabernero","Ronald Burkes","Mario Barugel","Yves Humblet","Gy\u00f6rgy Bodoky","David Cunningham","Jacek Jassem","Fernando Rivera","Ilona Koc\u00e1kova","Paul Ruff","Maria B\u0142asi\u0144ska-Morawiec","Martin \u0160makal","Jean-Luc Canon","Mark Rother","Kelly S. Oliner","Michael Wolf","Jennifer Gansert"],"doi":"10.1200\/jco.2009.27.4860","endpage":"4705","handles":[],"isbns":[],"issns":["0732-183X","1527-7755"],"issue":"31","journal":"Journal of Clinical Oncology","last_mentioned_on":1447718400,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20921465","http:\/\/dx.doi.org\/10.1200\/JCO.2009.27.4860"],"pmid":"20921465","pubdate":"2010-11-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"4697","subjects":["neoplasms"],"title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.","type":"article","uri":"http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.27.4860","volume":"28","mendeley_url":"http:\/\/www.mendeley.com\/research\/randomized-phase-iii-trial-panitumumab-infusional-fluorouracil-leucovorin-oxaliplatin-folfox4-versus-1"},"altmetric_score":{"score":5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5},"context_for_score":{"all":{"total_number_of_other_articles":7027828,"mean":6.2647750304584,"rank":1264602,"this_scored_higher_than_pct":81,"this_scored_higher_than":5737239,"rank_type":"exact","sample_size":7027828,"percentile":81},"similar_age_3m":{"total_number_of_other_articles":6432284,"mean":6.5815159239707,"rank":1206053,"this_scored_higher_than_pct":80,"this_scored_higher_than":5199573,"rank_type":"exact","sample_size":6432284,"percentile":80},"this_journal":{"total_number_of_other_articles":7023,"mean":12.611279122757,"rank":2779,"this_scored_higher_than_pct":59,"this_scored_higher_than":4195,"rank_type":"exact","sample_size":7023,"percentile":59},"similar_age_this_journal_3m":{"total_number_of_other_articles":6371,"mean":13.426597488226,"rank":2637,"this_scored_higher_than_pct":57,"this_scored_higher_than":3681,"rank_type":"exact","sample_size":6371,"percentile":57}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":5,"Professor > Associate Professor":18,"Librarian":1,"Student  > Doctoral Student":23,"Researcher":96,"Student  > Ph. D. Student":47,"Student  > Postgraduate":20,"Student  > Master":30,"Other":58,"Student  > Bachelor":15,"Lecturer":6,"Lecturer > Senior Lecturer":3,"Professor":7},"by_discipline":{"Medicine and Dentistry":217,"Social Sciences":1,"Decision Sciences":1,"Physics and Astronomy":3,"Mathematics":2,"Unspecified":14,"Pharmacology, Toxicology and Pharmaceutical Science":8,"Engineering":2,"Chemistry":4,"Economics, Econometrics and Finance":2,"Immunology and Microbiology":3,"Agricultural and Biological Sciences":47,"Computer Science":3,"Business, Management and Accounting":2,"Nursing and Health Professions":2,"Biochemistry, Genetics and Molecular Biology":17,"Philosophy":1}}},"geo":{"mendeley":{"EC":2,"AT":1,"NL":1,"US":5,"JP":3,"EG":1,"BR":5,"GB":5,"ZA":1,"FR":2,"DE":2,"ES":5}}},"posts":{"f1000":[{"title":"Panitumumab improves PFS in mCRC with wild-type KRAS.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21542198","citation_ids":[210390],"posted_on":"2010-12-01T00:00:00+00:00"},{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/6001956","license":"public","citation_ids":[210390],"posted_on":"2010-11-11T00:00:00+00:00","f1000_classes":[],"f1000_score":"2"}],"policy":[{"title":"Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy: Colorectal cancer (metastatic) - aflibercept: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA307\/documents\/colorectal-cancer-metastatic-aflibercept-evaluation-report2","license":"public","citation_ids":[1176911,2414820,5898084,2414824,7406858,15777348,931179,464330,2784654,21689706,15777350,945708,15777353,14491278,1983833,1429744,15777359,15777363,15777366,235707,589600,21689709,15777372,15777374,21689711,15777379,15777381,3219486,15777390,15777395,5586465,1903846,15750507,6073229,12918022,210531,3174285,380641,3368425,15777412,21689713,15777421,6077045,210494,2407679,15777441,15777444,8078462,850081,1752525,15777464,1223045,15777470,809217,2416454,210390,15660205,15777483,2480220,381688,1834844,5613031,15777502,15777511,15777516,21689717,21689718,8154575,15777523,1145378,15777353],"posted_on":"2013-06-21T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta307\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-3912e06cb81343df2459903b2a5cfc2d0c39c03fcd51530889b3f7c36cac6ee7.jpg"}},{"title":"Cetuximab and panitumumab for previously untreated metastatic colorectal cancer: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA439\/documents\/committee-papers","license":"public","citation_ids":[2414612,2784654,16034621,226440,4864573,2277138,4323582,20457847,20457848,234249,16034611,2226280,2771919,8203143,20457850,2563653,109150,16034642,20457851,887099,1202886,210390,20457854,20457855,968252,1744240,20455588,20457857,18645660,18645661,20457858,4042729,20457859,20457861,17193675,20457862,20457863,1487934,1353085,2232472,678365,2425801,548073,20457864,1517039,2259866,20455606,20457866,20457867,147599,2274575,2751850,679428,101592,20455601,20457868,2414612],"posted_on":"2015-11-17T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta439\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-058acc40dc5b10b5188d67b21789f14d0648d164f06484c06582493a2e1d0677.jpg"}}]}}